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1. Introduction 
Management and prognosis of the liver diseases highly depends on the advancement of the 
liver lesions. It is particularly important to distinguish patients at greatest risk of developing 
liver cirrhosis, liver failure and hepatocellular carcinoma. Liver biopsy remains the gold 
standard for evaluating the liver tissue. It allows not only for establishing the grade of 
inflammatory activity and the stage of fibrosis, but also for more accurate differential 
diagnosis and detection of coexisting liver diseases. Needle biopsy removes, however, only 
about 1/50,000 of the liver tissue and carries the risk of sampling error. Furthermore, the 
specimen should be sufficient in length (20-25 mm), width, fragmentation and number of 
complete portal tracts (at least 11) [Cholongitas et al., 2006]. Moreover, liver assessment is 
affected by significant interpretative error and interobserver variability of histological 
interpretation. Besides, many patients are reluctant to experience repeated biopsies, which 
limits the ability to monitor disease progression and the effects of treatments. 
Search for new non-invasive approaches have been initiated as a result of the limitations 
of the liver biopsy. Non-invasive tests for the assessment of the severity of chronic liver 
diseases seem to be an attractive option designed to replace liver biopsy in the near 
future.  
Ideal non-invasive marker of particular liver lesion should be reliable, liver specific, 
inexpensive and easy to perform. In addition, it should allow not only to diagnose particular 
liver problem but also to monitor its progression. Recently extensive research is performed 
to evaluate non-invasive techniques for the detection of liver fibrosis, necroinflammatory 
activity and steatosis in various liver diseases.  This chapter revises currently used non-
invasive techniques of liver assessment. 
2. Serum biochemical markers 
2.1 Serum markers of fibrosis in hepatitis 
The progression of liver fibrosis is a complex wound-healing process, that involves various 
types of cells and their mediators that eventually leads to the deposition and accumulation 
of various extracellular matrix (ECM) components.   
www.intechopen.com
  
Liver Biopsy 
 
266 
Serum biochemical tests including direct and indirect markers of fibrosis have been most 
widely investigated. Certain markers, especially cytokines, growth factors, metaloproteinases 
and their inhibitors may reflect balance or imbalance between fibrogenesis and fibrinolysis, 
revealing information about the progression of the disease.  
2.2 Direct markers 
Direct markers include profibrotic cytokines as transforming growth factor beta-1 (TGF 
beta-1), ECM components – glycoproteins as hyaluronan (HA), laminin, metaloproteinases 
their tissue inhibitors and others. Some of them demonstrated associations with liver 
fibrosis.  
Fibryl-forming collagens accumulate in the process of liver fibrosis being important 
components of extracellular matrix.  The most extensively studied collagen is PIIINP, an 
aminotreminal peptide of procollagen III, that is cleaved from procolagen III during its 
secretion by fibroblasts. Therefore, it is mainly considered to be a marker of fibrogenensis, 
rather than fibrosis. PIIINP was found proportional to the liver fibrosis in several studies. 
However, this parameter should be validated in further studies, as it is too early to 
recommend its use as a single marker [Leroy et al., 2004].  
Transforming growth factor beta 1 (TGF-beta 1) is a cytokine that activates fibrogenesis and 
inhibits fibrinolysis. This protein stimulates mesenchymal cells and increases production of 
ECM components. TGF-beta 1 was found to be related to the liver fibrosis in patients with 
CHC and CHB [Marek et al., 2003].   
Laminin is a glycoprotein of ECM consisting of 3 different polipeptide chains ǂ, ǃ, and Ǆ. 
Laminins take part in the cellular adhesion, stimulate cellular growth and act as cellular 
mediators. This protein is also considered to be a marker of the liver fibrosis. In various 
studies it was found to be related to the degree of the liver fibrosis in patients with CHC 
[Walsh et al., 2000]. 
Hyaluronic acid (HA) a glycosaminoglycan produced by fibroblasts that seems to be a 
major component of extracellular matrix. Liver sinusoidal cells are responsible for 
degradation of its particles. Therefore elevated HA serum levels may reflect endothelial 
dysfunction associated with the progression of fibrosis. Several studies proved correlation 
between HA serum levels and hepatic fibrosis, it has, however limitations in 
distinguishing exact stages [Patel et al., 2003]. HA was validated in HCV, HBV and 
HCV/HIV coinfected patients. Serum concentrations of HA were found to be related to 
the level of fibrosis. However, in lower fibrosis stages serum HA levels may overlap, 
therefore the parameter is more reliable in advanced stages of fibrosis [Resino et al., 2010]. 
HA< 60 ug/l exclude fibrosis and extensive fibrosis, whereas values >110 ug/l predicted 
cirrhosis [McHutchinson et al., 2002]. 
Metaloproteinases (MMPs) and their tissue inhibitors (TIMPs) are proteins involved in the 
regulation of fibrogenesis and fibrinolysis. MMPs are secreted by fibroblasts and Kupfer 
cells in inactive form that requires further cleavage for functional capability. They are 
involved in degradation of extracellular matrix components and are regulated by tissue 
inhibitors (TIMPs). MMP-2 is an enzyme up-regulated by collagen type II, that was found to 
be positively related to the liver fibrosis. Similar correlations were found for TIMP-1 and 
TIMP-2. Moreover, TIMP-1 was found to be very sensitive and displayed good specificity 
for the detection of liver cirrhosis [Boeker et al., 2002]. In combination with HA and PIIINP, 
TIMP-1 showed good accuracy for the diagnosis of extensive fibrosis and cirrhosis [Leroy et 
al., 2004].  
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Although direct markers are less expensive than the liver biopsy, they are still costly and are 
not available in most clinical settings. Therefore, none of those biomarkers is  until now  in 
frequent use except for research studies.   
2.2.1 Indirect markers 
Indirect markers associated with fibrosis, such as routine biochemistry, platelets, and alpha-
2-macroglobulin, are widely available in daily clinical practice. Biochemical tests mainly 
include aspartate (AST) and alanine aminotransferase (ALT) activity and prothrombine 
time. They are either tested alone or in combination, which enhances their value. 
Prothrombine time, a well-known marker of hepatic dysfunction, was negatively correlated 
to fibrosis even in its earlier stages [Croquet et al. 2002]. Thrombin is believed to be trapped  
by the hepatic sinusoidal capillary network and bind to the receptors on the surface of 
activated hepatic stellate cells. 
AST levels usually increase in patients with liver fibrosis as a result of reduced clearance by 
sinusoidal capillary network. AST/ALT ratio was found related to the presence of liver 
cirrhosis with high predictive values for ratio exceeding 1. Nevertheless, not all studies 
confirm such results. Diagnostic value of AST/ALT ratio was improved by its combination 
with platelet count below 150 G/l. Number of platelets declines with the progression of liver 
fibrosis as a consequence  of sequestration in the spleen but also reduced thrombopoetin 
production.  
Indirect markers are cost-free, thus they have not been tested in less advanced cases of liver 
fibrosis. Recent studies combine these markers to produce valuable scores.  Several indirect 
markers and have been incorporated into composite panels that have been developed to 
evaluate the presence hepatic necroinflammation and fibrosis.  
FibroTest- Acti-Test consisting of the panel of selected biochemical markers was designed to 
evaluate liver fibrosis and necroinflammatory activity in chronic hepatitis C (CHC) 
[Poynard et al., 2002; Myers et al., 2003]. The test consist of six biochemical markers: alfa2-
macroglobulin (A2-M), haptoglobin (HPT), gamma glutamyltranspeptidase (GTP), total 
bilirubin, apolipoprotein A1 (ALP-A1) and ALT that are adjusted to the patient age and 
gender in a patented algorithm. No single blood test possesses sufficient negative or positive 
predictive value to substitute for liver biopsy, especially for the diagnosis of moderate 
fibrosis (F2).  Each of the components adds complementary value to, the estimation of 
fibrosis and necroinflammatory activity. A2-M is a protein synthesized by hepatocytes, 
stellate cells and granulomas, which serum concentration increases during stellate cell 
activation in the course of fibrogenesis. As proteinases inhibitor it can increase fibrosis by 
inhibiting the breakdown of extracellular matrix proteins. HPT is a protein synthesized by 
the liver which serum level decreases with fibrosis. This decline does not depend on 
hemolysis or hepatic insufficiency. In the circumstances of the liver fibrosis HPT synthesis is 
decreased by hepatic growth factor.  ALP-A1 is a protein synthesized by hepatocytes, 
responsible for the transport of the cholesterol. In liver fibrosis, its release is hampered by 
the ECM collagen fibers, moreover its transcription is equally reduced. Serum 
apolipoprotein A1 levels declines in the presence of fibrosis. Bilirubin is a pigment resulting 
from the degradation of hemoglobin, which in normal conditions is taken up from the 
blood, conjugated and excreted in bile. Bilirubin increases in liver fibrosis. Hepatitis C virus 
infection modifies the transporters of bilirubin that could explain the increase observed in 
the early stages of fibrosis. GTP  is an enzyme synthesized by hepatocytes, which increases 
with fibrosis on unknown mechanisms, that are independent of the growth in 
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aminotransferases and bilirubin. It is believed that epidermal growth factor stimulates the 
synthesis of GTP during of fibrogenesis. ALT is an enzyme synthesized by hepatocytes, 
which increases in serum when necrosis and hepatic tissue inflammation occur. Fibrotes-
Actitest was proven to have high predictive value in CHC patients before and after antiviral 
treatment [Poynard et al., 2001], in patients with persisting normal ALT activity [Colletta et 
al., 2005], coinfected with HIV [Myers et al., 2003]. The test was also found useful in chronic 
hepatitis B (CHB) [Myers et al., 2003], alcoholic liver disease [Naveau et al., 2005], 
nonalcoholic fatty liver disease (NAFLD) [Ratziu et al., 2006] and hemochromatosis 
[Adhoute X et al., 2006].  The test was also confirmed to other  single direct and indirect 
markers as well as the test panels. Its main disadvantage are false positive results induced 
by ribavirin treatment on HPT levels. Numerous publications were released concerning this 
method of assessment in various liver diseases. It enables direct extrapolation from the 
results of the test to the stages of fibrosis in different scoring systems (Table 1). The test is 
available on commercial bases. Thus, the chief researcher involved in validation of the test 
has financial interests in its manufacturing company.   
 
Fibrotest 
METAVIR fibrosis stage 
estimate 
Knodell fibrosis stage 
estimate 
Ishak fibrosis stage 
estimate 
0.75-1.00 F4 F4 F6 
0.73-0.74 F3-F4 F3-F4 F5 
0.59-0.72 F3 F3 F4 
0.49-0.58 F2 F1-F3 F3 
0.32-0.48 F1-F2 F1-F3 F2-F3 
0.28-0.31 F1 F1 F2 
0.22-0.27 F0-F1 F0-F1 F1 
0.00-0.21 F0 F0 F0 
Table 1. Conversion between the results of FibroTest and fibrosis stages in METAVIR, 
Knodell and Ishak scoring systems. Fibrosis scoring systems. 
Beside Fibrotest-Actitest, more panels of direct and indirect markers were developed.  
FibroSpect evaluates liver fibrosis by analyzing the following parameters: hyaluronic acid, 
tissue-inhibited matrix metalloproteinase inhibitor-1 and ǂ-2 macroglobulin [Patel et al., 
2004]. The score is licensed and commercially available in the USA. Validated in several 
studies, the test was proven to be effective for excluding significant fibrosis and cirrhosis. 
Positive predictive values for detecting fibrosis were found much lower than negative 
values for excluding significant fibrosis or cirrhosis [Zaman et al., 2007]. 
Fibrosure combines quantitative results of the following parameters: A2-M, HPT, GTP, total 
bilirubin, ALP-A1 and ALT with a patient’s age and gender in a patented artificial 
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intelligence algorithm to create a measure of fibrosis and necroinflammatory activity in the 
liver. The test is an American form of Fibrotest and provides continuous numerical 
assessment of liver fibrosis and necroinfalmmatory activity corresponding to METAVIR 
scoring system. Values <0.48 exclude significant fibrosis while a score >0.78 is highly 
predictive for the liver cirrhosis. Values <0.36 indicate minimal activity, while  scores>0.62 a 
specific for severe necroinflammatory activity [Poynard et al., 2004].  
Hepascore includes bilirubin, GTP, A-2M, HA, age and gender [Adams et al. 2005]. A score 
>0.5 indicated significant fibrosis with 92% of specificity and 67% of sensitivity. While scores 
<0.5 had 74% specificity and 88% sensitivity to exclude advanced fibrosis.  A cutoff of 0.84 
had a 71% specificity and 89% of sensitivity for the prediction of liver cirrhosis.  However, 
there was a significant overlap between patients with mild and moderate fibrosis.  
Fibroindex was a proposed score that includes: platelets, AST levels and gammaglobulin 
according to the formula: Fibroindex=1.738 – 0.064 x platelets (104/mm3) + 0.005 x AST 
(IU/l) + 0.463 x gammaglobulin (g/dl). Two threshold were proposed for the diagnosis of 
significant fibrosis. A score >1.25 confirmed fibrosis with 94% of specificity and >2.25 with 
97% of specificity [Koda et al. 2007].  
Forns score combines: age, GTP, cholesterol level, platelet count according to the formula: 
Forns score=7.811-3.131 x ln platelets (g/l) +0.781 x ln GTP(IU/l)+3.647 x ln age(years)-0.014 
x cholesterol [Forns et al. 2002]. A score <4.2 excluded and a score>6.9 confirmed significant 
fibrosis. The main limitation of the scale is that the result is indefinite in  many patients and 
no thresholds were created for the diagnosis of extensive fibrosis or cirrhosis. Thus, lipid 
abnormalities observed in hepatitis  patients raise concerns related to the utility of the scale 
and requires further validation for the use in routine clinical practice. 
APRI score is AST/platelets ratio calculated as (AST/upper normal limit X 100/platelet 
count) [Wai et al 2003] originally proposed for hepatitis C patients. In original study a score 
<0.5 ruled out significant fibrosis, a score <1.0  excluded cirrhosis and a score >2.0 suggested 
cirrhosis with good predictive value. Nevertheless, subsequent studies in hepatitis C and 
HIV coinfected patients had much poorer outcome. This score was found to be useful to 
exclude significant fibrosis and particularly cirrhosis with around 90% certainty also in HCV 
infected  hemodialysis patients [Schiavon  et al., 2007]. The results were, however much 
worse in alcoholic patients as alcohol may have direct effects on AST activity and platelet 
count. Therefore this limitation should be taken into account in daily clinical practice 
[Trabut et al., 2009]. APRI may be used as an easy first-line investigation, however, not as 
the only tool as it has moderate diagnostic utility for the prediction of fibrosis in HCV-
infected patients. Its major role appears to be the exclusion of significant fibrosis and 
cirrhosis, which can be achieved with acceptable accuracy in at least one third and three 
quarters of patients, respectively [Shaheen and Myers, 2007]. 
FIB-4 uses the following formula: (age X AST/platelets X ALT)1/2 [Vallet-Pichard et al., 
2007]. Values <1.45 ruled out extensive fibrosis and >3.25 confirmed the diagnosis with 
around 90% of accuracy in comparison to the histological results in the Ishak scoring 
system. Significant proportion of patients fell into indeterminate range of results.  
Although these test give promising results in detecting advanced fibrosis their ability to 
replace liver biopsy is still not probable as some of them have not been sufficiently validated 
[Bourliere 2006]. Some of the scores like APRI may be influenced by other factors like for 
example alcohol abuse that may influence on the level of indirect markers in the scale. 
Diagnostic panels were presented in Table 2. 
www.intechopen.com
  
Liver Biopsy 
 
270 
Score Parameters involved Formula Reference 
Fibrotest-
Actitest 
alfa2-macroglobulin
haptoglobin 
GTP 
total bilirubin 
apolipoprotein A1 
ALT 
Age 
gender
Patented and commercially 
used 
Poynard 
et al.  2002 
FibroSpect 
hyaluronic acid
tissue-inhibited matrix 
metalloproteinase 
inhibitor-1 
ǂ-2 macroglobulin
Licensed and commercially 
used 
Patel  et 
al. 2004 
FibroSure 
alfa2-macroglobulin
haptoglobin 
GTP 
total bilirubin 
apolipoprotein A1 
ALT
The USA patented form of 
Fibrotest-Actitest 
Poynard 
et al 2004 
Hepascore 
Bilirubin
GTP 
ǂ-2 macroglobulin 
hyaluronic acid 
age 
gender
Hepascore=y/1+y;
y=exp [4.185818 –(0.0249 x 
age +(0.7464 x sex + 1.0039 x 
ǂ2-macroglobulin +(0.0302x_ 
hyaluronic acid)+(0.0691 x 
bilirubin)-(0.0012 x GGT)]
Adams et 
al. 2005 
Fibroindex 
PLT 
AST 
gammaglobulin 
Fibroindex= 1.738 – 0.064 x 
PLT (104/mm3) + 0.005 x AST 
(IU/l) + 0.463 x 
gammaglobulin (g/dl)
Koda et 
al. 2007 
APRI 
AST 
PLT 
APRI = AST level (/ULN)      
x100 
PLT (109/L)
Wai et al. 
2003 
FIB-4 
Age
AST 
ALT 
PLT
FIB-4=  (age X AST/PLT X 
ALT)1/2 
Vallet-
Pichard et 
al. 2007 
Abbreviations: AST – aspartate aminotransferase, ALT – alanine aminotransferase, GTP- gamma 
glutamyltranspeptidase, UNL – upper normal limit, PLT – platelet count 
Table 2. Serum diagnostic panels of direct and indirect markers. 
2.3 Serum markers of steatosis 
Several studies proposed various tests to distinguish between simple steatosis and NASH in 
patients with NAFLD. The most important parameters are acute phase proteins as they 
enable to establish NASH. Several markers of inflammation were extensively studied in 
relation to fatty liver disease. C-reactive protein (CRP) is an acute phase parameter that is 
produced in the liver and increases in various inflammatory conditions. The evaluation of 
serum CRP levels was found to be associated with NASH and helps to differentiate this 
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condition from simple steatosis. Furthermore, high levels of high-sensitivity CRP were 
found to be associated with extensive liver fibrosis in NASH [Yoneda et al. ,2007].  
Nevertheless, study conducted in children with liver steatosis revealed that fatty liver itself 
may not be a cofactor in stimulating inflammatory markers in obese patients. Obese children 
with NAFLD may have simple steatosis and their increased inflammatory markers are 
therefore compatible with those expected in obesity [Neuman et al. ,2010]. 
Another acute phase protein used to distinguish NASH from non-NASH patients is plasma 
pentraxin-3 (PTX 3) a novel marker that seems to be promising in assessing the severity of 
fibrosis. Plasma PTX-3 levels were, however, found increased not only in NASH, but also in 
other cardiovascular and inflammatory conditions and vasculites [Yoneda et al., 2008].  
Interleukin-6 seems to be another marker playing an important role in fatty liver disease. 
This biomarker is a cytokine synthesized in hepatocytes, endothelial cells, adipocytes and 
cells of the immune system, that rises in NAFLD and indicates inflammatory activity and 
liver fibrosis [Wieckowska et al. , 2008].  
Tumor necrosis factor-alpha (TNF-alpha) is another proinflammatory cytokine which role in 
NASH was clearly established. As levels of TNF-alpha are increased in NASH, anti-TNF-
alpha therapy was found effective in the improvement of liver histology and normalization 
of aminotransferase levels. 
Cytokeraitn-18  is  a marker of hepatic apoptosis  and is utility in the detection of NASH is 
based on the observation that apoptosis is prominent in NASH and absent in simple 
steatosis. Its use is, however, so far limited to research areas [Wieckowska et al. , 2008].  
As oxidative stress has been found to play an important role in NASH pathogenesis several 
parameters were evaluated in various studies:  vitamin E levels, glutathione peroxidase 
activity and superoxide dismutase activity [Hardwick et al.,2010]. None of these markers 
reflect liver histology in NASH, therefore its clinical value is still questionable and were not 
entirely defined yet. The assessment of the liver fibrosis is an important component in the 
evaluation of NASH as end stage liver disease is constantly present in this state. Several 
matrix components have been studied in various trials: HA, TGF beta-1, TIMP and other 
markers. Nevertheless so far none of them entered clinical use.  
To avoid liver biopsy several noninvasive panels of serological markers have been 
developed to assess the presence of hepatic necroinflammation and steatosis. SteatoTest is a 
quantitative test designed to estimate liver steatosis especially in patients with metabolic 
syndrome [62]. NASH test is a variation of SteatoTest and ActiTest for the differentiation of 
simple steatosis from NASH and should be performed only if SteatoTest is positive. The 
scores combine various parameters. The NASH test combines total bilirubin, GGT, ǂ2-
macroglobulin, apolipoprotein A1, haptoglobin and ALT, and is adjusted for age and 
gender plus weight, height, AST, serum glucose, triglycerides, cholesterol and SteatoTest. 
NASH FibroSURE is the USA patented algorithm combining quantitative results of 10 
biochemical parameters,  including A2M, HPT, ALP-A1, bilirubin, GTP, ALT, AST, total 
cholesterol, triglycerides, and fasting glucose, in relation to the age, gender, height, and 
weight. The registered algorithm  provides quantitative alternate markers for liver fibrosis, 
hepatic steatosis, and NASH. Markers of fibrosis are corresponding to METAVIR scoring 
system. Marker of hepatic steatosis varies from S0 to S3 and is corresponding to 0% to >66%. 
In a study conducted on patients with significant (>5%) steatosis score a value >0.5 
confirmed steatosis with high sensitivity and specificity [Poynard et al., 2005]. The test also 
provides a diagnostic assessment of the presence of NASH using three broad categories N0-
N2 corresponding to “Not NASH,” “Borderline NASH,” and “NASH” per the Kleiner 
classification [Kleiner et al.;2005]. 
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Other tests combine both direct and indirect markers or other clinical parameters: age, 
gender, BMI, AST, AST/ALT ratio, hyaluronan [Palekar et al., 2006] or adiponectin and 
collagen type IV [Shimada et al., 2007].  
Various test panel were compared with one another. The results are, however, ambiguous  
and vary from study to study. Although patented commercial tests seem to present a higher 
diagnostic value, simply non-patented panels are much easier available.  
3. Transient elastography 
Non-invasive assessment of the liver fibrosis is also possible by transient elastography. The 
technique is performed by device called Fibroscan that enables the assessment of the liver 
stiffness. The device holds an ultrasound probe in a vibrating piston that induces elastic 
vibrations propagating through the liver. The reflected waves captivated by a transducer 
enable to measure the liver elasticity that is inversely related to the speed of the waves 
[Sandrin 2003]. After several measurements, calculated mean value enables the exact 
assessment of liver fibrosis. This  method was proven precise enough when compared to the 
liver biopsy and evaluates a portion of the liver 500 times bigger than conventional method 
[Castera 2005]. Transient elastography is described in detailed in another chapter of this book. 
It was also used in combination with serum markers of fibrosis. The Fibro-Stiffness index is 
a panel consisting of liver stiffness measured by Fibroscan, platelet count and prothrombin 
time. The method demonstrated superior diagnostic performance to liver stiffness obtained 
by elastography alone, the APRI, the Forns score and the FibroIndex for significant and 
severe fibrosis and liver cirrhosis. The diagnostic value of the Fibro-Stiffness index for liver 
cirrhosis was increased by combination with serum HA levels [Ichino et al., 2010]. 
Various test panles were validated either compared to elastography or used simultaneously 
with this method. The most promising results were obtained were both serum markers and 
elastography were used together. 
4. Imaging techniques  
Conventional imaging techniques that include ultrasound with Doppler, CT and MRI can be 
used to evaluate advanced liver cirrhosis. Their ability to detect minor lesions is, however, 
limited [Hussain 2005]. 
4.1 Hepatic ultrasound  
Ultrasonography is simple, inexpensive, easy to reproduce and can be repeatedly used to 
assess changes over time. It is a first-line imaging technique, a simple non-invasive method, 
that is widely used in clinical practice to detect fatty infiltration of the liver. It assesses the 
presence of steatosis detecting a hyperechogenic parenchyma of the liver displayed as 
“bright liver “ or “blurring of the vascular margins”. An ultrasound index for quantitative 
assessment of the liver steatosis is the hepato-renal contrast. Normal liver shows an 
echostructure similar to renal parenchyma. In liver steatosis the increased echogenity forms 
hepato-renal contrast.  Severity of liver steatosis was assessed according to a discrepancy in 
ultrasonographic liver-kidney densities. The hepato-renal index was supposed to quantify 
the severity of liver steatosis to a lower limit of 5% [Webb et al. , 2007].   
Spleen longitudinal parameter is another simple, noninvasive and easy to perform 
parameter, that could differentiate between NAFLD and NASH better than serum markers 
with values exceeding 11.6 cm for predicting NASH.  
www.intechopen.com
 
Non-Invasive Assessment of the Liver – Serum Markers and Imaging Techniques 
 
273 
When the degree of steatosis is less than 30%, sensitivity of this technique is low. Moreover, 
it is impossible to detect inflammatory changes of the hepatic parenchyma and to 
differentiate  between simple steatosis and staeatohepatitis. Therefore, it is very difficult to 
distinguish between the liver steatosis  and liver fibrosis as both changes look similar on 
ultrasound. 
The biggest limitation of this technique is morbid obesity as ultrasonographic examination is 
difficult to perform in such patients.  Ultrasonography is, however, insufficient for detecting 
early and intermediate stages of fibrosis.  
4.1.1 Doppler ultrasound 
Doppler ultrasound is another helpful tool in the diagnosis of steatosis. Hepatic parenchyma 
perfusion abnormalities were observed in NASH. Altered hepatic hemodynamics can be 
described by various parameters including, among others, hepatic vein Doppler pattern and 
Doppler perfusion index (DPI), which is a ratio between hepatic arterial blood flow and total 
liver blood flow. DPI allows for the detection of overt liver metastatic disease and helps to 
differentiate between benign and malignant focal hepatic lesions [Kyriakopoulou  et al. 
,2008]. DPI was also found predictive of the liver steatosis in patients with NAFLD in the 
study conducted on a small group of patients, therefore it requires further evaluation 
[Dugoni et al. 2007]. Conventional Doppler ultrasound examination of hepatic vasculature 
is, unfortunately not a good tool to evaluate mild and moderate fibrosis. Data reporting the 
use of hepatic vein blood flow pattern assessment suggests improvements in detecting 
advanced fibrosis and cirrhosis [Bertzigotti et al., 2010].  
4.1.2 Contrast-enhanced ultrasonography 
This technique allows to overcome limitations of simple ultrasonography. Hepatic vein 
transit times (HVTT) were evaluated with microbubble contrast agent and were found to 
predict disease severity in patients with hepatitis C. The uptake of another contrast agent 
levovist was decreased in NASH due to  cell injury, when compared to NAFLD. The study 
was, however conducted on a small group of patients and should be validated on a larger 
cohort to establish the role of this technique in clinical practice. 
4.2 Computed tomography 
Computed tomography (CT) provides improved resolution of early liver cirrhosis in the 
absence of portal hypertension but remains unhelpful in a detection of fibrosis. Even more 
advanced variations as helical and multidetector row CT reveal early morphological 
changes with cirrhosis but do not identify fibrosis. 
Nevertheless, this  conventional technique is a helpful tool in detecting steatosis. Moreover, 
non-contrast enhanced CT is the best way to identify and characterize hepatic steatosis. 
Changes in signal sensitivity are related to the liver density, therefore as liver density 
decreases, the liver steatosis increases. Although abdominal ultrasound is more sensitive in 
the diagnosis of fatty liver disease, CT scans are more adequate when the fat deposition is 
focal.  They may also be used to evaluate thickened abdominal fatty tissue and to measure 
the fat in the liver [Davidson et al., 2006]. CT scans may also be used to visualize enlarged 
spleen and portal hypertension, which may suggest advanced fibrosis. Calculation of the 
liver-to-spleen attenuation ratio allows grading of steatosis [Park et al., 2006]. As the images 
appear enhanced, non-contrast CT is chosen for detecting steatosis. Focal fatty lesions may 
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be detected by dual-energy CT scans or by contrast enhanced CT. Figure 1 provides picture 
of multiple fatty lesions in the liver. 
However the difficulty to identify intermediate fibrotic stages and the uselessness in the 
follow-up of the patients due to the exposure to radiation are major limitations of CT. 
 
Fig. 1. Computed tomography with multiple focal lesions in the liver (A) of lower density 
than the liver parenchyma after contrast-enhancement (B) corresponding to hemangiomas.  
4.3 Magnetic resonance imaging 
Magnetic resonance imaging (MRI) reliably identifies cirrhosis but does not show earlier 
stages of fibrosis. Specific features on MRI including hepatic vein narrowing, caudate to 
right lobe ratio, and expanded gallbladder fossa, reliably identify cirrhosis but remain 
absent in earlier stages of fibrosis [Numminen et al., 2005]. This technique provides an 
accurate and fast evaluation of the liver steatosis even if the degree is low (around 3%). 
Good correlation between liver steatosis, MRI and liver biopsy have also been recently 
demonstrated [Hussain 2005]. Phase-contrast imaging is used for the quantitative 
assessment of fatty infiltrations in various liver diseases. Lower intensity in T1-weighted 
images may be used in the detection of focal fat depositions [Szczepaniak  et al., 2005].  
Significant number of technological advances in developing clinical applications for MRI of 
the liver have been made over the past decade. Recent improvements focused on using the 
physiological and biomechanical properties of human liver tissue to improve the detection 
of focal and diffuse pathological conditions of this organ. New techniques such as magnetic 
resonance (MR) spectroscopy, diffusion-weight MR, MR elastography are evaluated to 
examine fibrosis [Talwalkar 2008].   
4.3.1 Contrast-enhanced magnetic resonance imaging 
The development of contrast-enhanced imaging of the liver have been enabled by the 
introduction of gadolinium chelates to clinical practice. Changes in hepatic parenchyma 
were described in various studies after contrast-enhanced imaging by MRI [Gandhi et al., 
2006]. Early irregular enhancement corresponds to the increased necroinflammatory activity 
in the liver histology due to higher numbers of macrophages. Whereas, a postponed, 
heterogeneous enhancement is related to hepatic fibrosis as a result of bright-appearing 
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reticulations. This finding may be explained by a reduced distribution of gadolinium in 
extracellular spaces of the liver [Semelka et al., 2001]. Contrast enhancement depends on the 
contrast agents. Supermagnetic iron oxide (SPIO) contrast media result in hypointensity 
within hepatic parenchyma as they accumulate in reticulo-endothelial cells [Yamashita et al., 
1996]. The most interesting findings were, however, obtained by sequential administration 
of gadolinium followed by SPIO contrast agents. Highly accurate SPIO-based images were 
even improved in accuracy for the detection of liver fibrosis architecture [Aguirre et al., 
2006]. Further validation of semi quantitative fibrosis criteria is required to verify the 
diagnostic performance of this technique.  
4.3.2 Magnetic resonance spectroscopy 
Magnetic resonance spectroscopy (MRS) has been available for the last twenty years 
allowing evaluation of metabolism of various tissues. The liver is considered to be an ideal 
organ for MRS due to its anatomical location and increased metabolic demands. MRS is 
usually used to evaluate signals from hydrogen, which allows for quantitative assessment of 
lipids and from phosphorus, which reflects cellular turnover and energy state [Solga et al., 
2005]. MRS of the liver is performed after a standard MR imaging for localization. Special 
MR pulse sequences are used to produce spectroscopic data within the suitable anatomical 
location and volume of interest. Peak area of metabolite signal is directly related to its 
concentration, which may be expressed in absolute or relative conditions. As the absolute 
quantification is difficult to obtain in vivo, many studies use metabolite ratios for the 
evaluation of spectral profiles. Peak areas of the spectrum are compared to standards for 
correlation with the strength of MR signal. The most widely used standard is adenozyne 
triphosphate (ATP), taking into account its natural distributions in the tissues. Changes in 
phospholipids metabolism, reflected in increased phosphomonoesters signal or increased 
phopsphomonoesters/phosphodiesters ratio in patients with liver cirrhosis, are believed to 
be associated with regenerating activity – extensive membrane remodeling.  
MRS represents useful method for highly accurate noninvasive measurement of liver 
steatosis [Friedrich-Rust 2010]. This technique measures the fat proton fraction and hepatic 
trigliceryde level. Concentration exceeding 5% is a limit of the detection of steatosis. MRS 
describes metabolic processes of cellular regeneration, therefore it can assess the disease 
severity in NASH. This technique is probably more accurate for the diagnosis of NAFLD but 
it requires further validation in humans.   
The studies have to be, however, repeated and validated on the larger number of patients 
with various liver diseases using unified methods. 
4.3.3 Diffusion weight magnetic resonance imaging 
Diffusion-weighted magnetic resonance imaging (DWI) has been widely used for the early 
detection of cerebral ischemia. This technique measures the freedom of water proton 
diffusion in tissues and was recently facilitated to be used for abdominal imaging 
[Naganawa et al., 2005]. As collagen is not reach in unbound water, therefore in the liver 
fibrosis the amount of water proton diffusion is restricted in affected tissue.  DWI produces 
a signal inversely related to the freedom of water proton diffusion. Tissues with reduced 
distribution are brighter than normal. The strength of diffusion weighting is described by 
“b” value of the sequence, which rises with time and amplitude of the gradients responsible 
for the diffusion. Apparent diffusion coefficient (ADC) of water proton in tissues may be 
calculated from DWI images. It is determined by the grade of the log intensity set against b 
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value [Girometti et al., 2007]. Possibility to display the calculated ADC values as images 
enable the quantitative analysis by the measurements of the mean values within region of 
interest. This measurement is usually performed in the right hepatic parenchyma, where 
major vessels are not present.  
Patients with liver cirrhosis were found to have lower ADC compared to healthy 
individuals. Nevertheless, the results of the studies in patients with various stages of fibrosis 
are ambiguous with respect to demonstrating a specific relationship between ADC values 
and fibrosis stage [Koinuma et al., 2005].  
Before the DWI becomes more widely used in clinical practice, the studies would have to be 
conducted on a larger number of patients and properly validated in relation to different 
hardware and sequencing profiles as currently comparisons are difficult.  It was also 
detected that significant hepatic iron accumulation may considerably reduce signal intensity 
making DWI impossible in patients with hemochromatosis [Aube et al., 2004]. Fat 
suppression techniques are necessary in DWI performed in the liver steatosis as otherwise 
imaging is seriously affected.  
4.3.4 Magnetic resonance elastography 
Many pathological  processes as malignancies and liver fibrosis result in increased liver 
stiffness, which may be detected by physical examination on palpation. Normal liver tissue 
is similar to fatty tissue on palpation, whereas cirrhotic liver is much harder. Recent reports 
suggest that the stiffness of hepatic matrix may influence continued differentiation of 
hepatic stellate cells and the production of fibrosis. Beside ultrasonography-based 
elastography, a MR-based elastography was described for evaluation of the stiffness of 
various tissues. The technique uses a phase-contrast method to display the propagation 
characteristics of acoustic sheer waves generated within the organ of interest [Kruse et al., 
2000]. Elastography is usually added to a conventional MR examination of the abdomen 
with pneumatic or electromechanical driver placed on abdominal wall in the supine patient. 
The device is used to generate  mechanical waves that propagate in the liver at various 
frequencies [Yin et al., 2007]. A specialized  phase contrast MRI sequence,  is subsequently 
used to image the propagating waves in the liver with motion-encoding gradients that are 
oscillated along with applied movements enabling clear imaging of the waves with very 
small amplitudes. Provided images represent displacement generated by shear wave 
propagation in the tissue. They are subsequently processed using a particular inversion 
algorithm to produce quantitative images describing the tissue stiffness called elastograms. 
The imaging allows for the measurement of mean elasticity values within the liver, 
presented in in kilopascals, as in the case of ultrasound-based transient elastography. 
Mean liver stiffness in patients with chronic liver diseases was found significantly increased, 
compared to healthy volunteers in various studies [Klatt et al., 2006]. A quadratic 
relationship between histological fibrosis stage and elasticity measurements were observed 
in the studies using ultrasound-based transient elastography. MR elastography was 
detecting stages 2 to 4 with good sensitivity and specificity. Thus, no relationship between 
hepatic steatosis and liver stiffness was found. MR elastography was a useful tool to exclude 
the presence of the liver fibrosis suggesting that this technique could be valuable in finding 
indications for the liver biopsy [Yin et al., 2007].  
Several advantages of this method were observed in relation to its potential use in different 
populations: potential assessment of entire hepatic parenchyma, operator independence and 
the ability to obtain a conventional abdominal MRI at the same time. Correspondingly to 
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other techniques, the equipment and sequences have to be standardized in order to increase 
the accuracy of the results and enable comparison of different studies. Further assessment is 
also necessary to characterize the procedure including its reproducibility among patients 
with progressive liver disease.  
4.3.5 Multi-echo magnetic resonance 
Multi-echo MRI allows simultaneous T2 and fat content evaluation. This method can be 
used to define the fat-to-water ratio as well as T2 values [O’Regan et al., 2008].  
4.3.6 Magnetic resonance cholangiopancreatography 
Magnetic resonance cholangiopancreatography (MRCP) is a well-established non-invasive 
imaging method that creates images of the biliary tree and pancreatic duct without the 
necessity of intravenous contrast. The images are corresponding to those from endoscopic 
retrograde cholangiopancreatography (ERCP). The most common indications for this 
technique include choledocholithiasis, primary sclerosing cholangitis or stricture of bile 
ducts and others. MRCP also plays an important role in other conditions involving 
cholangiohepatitis, inborn malformations, tumors and other cysts. The biggest advantage of 
this technique is the lack of contrast administration, relative operator independence and 
possibility to evaluate both sides of obstructed ducts with exact stricture size and 
morphology. Example of MRCP imaging was presented in Figure 2.  
 
 
Fig. 2. MRCP image showing the liver of patient with primary sclerosing cholangitis and 
numerous fibrous septa within the liver with coexisting splenomegaly. 
A reliable and valuable noninvasive method to assess hepatic fibrosis would be a very 
useful clinical tool.  Several MR techniques or their combinations are still evaluated to meet 
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these requirements and are very promising. Further research is, however necessary to create 
true functional hepatic imaging.  
Clinical utility of imaging techniques is still under evaluation. Advanced MRI techniques 
are available in tertiary medical centers  and it will probably take time before they become 
widely available.  Furthermore, even  with this technique some patients may be unable or 
unwilling to undergo the examination. 
5. Conclusions 
Combination of non-invasive methods like Fibro-test and elastography may substitute the 
liver biopsy in a near future. They are reliable in patients either with no or progressed 
fibrosis. Evaluation of intermediate states is, however, difficult. For this reason the liver 
biopsy remains a most valuable tool in evaluation of the liver and according to current 
guidelines treatment decisions should be made after liver biopsy. Thus, non-invasive 
methods may be still an option for patients with contraindications to the liver biopsy or a 
helpful monitoring tool for those who are reluctant or unable to undergo repeated biopsies. 
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complications in liver biopsy. Additionally, this book provides also the references for the new technology of liver
biopsy including the non-invasive elastography, imaging methods and blood panels which could be the
alternatives to liver biopsy. The non-invasive methods, especially the elastography, which is the new
procedure in hot topics, which were frequently reported in these years. In this book, the professionals of
elastography show the mechanism, availability and how to use this technology in a clinical field of
elastography. The comprehension of elastography could be a great help for better dealing and for
understanding of liver biopsy.
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